Background: The relevance of prostate-specific membrane antigen (PSMA) targeting in the clinical management of prostate cancer (PCa) is continually increasing, entailing the development of PSMA-targeted molecular probes. Recently, a first PSMA-targeted theranostic concept has been successfully implemented by [ 68 Ga/ 177 Lu]PSMA-I&T. To further exploit the excellent PSMA-targeting characteristics and in vivo performance of the PSMA-I&T platform, [
In]PSMA-I&T SPECT/CT (4 h p.i.), followed by prostatectomy and radioguided extended pelvic lymphadenectomy (24 h p.i.). In [ 
Findings
Modern clinical management of prostate cancer increasingly relies on exploiting the prostate-specific membrane antigen (PSMA) as a molecular target both for imaging and for treatment of prostate cancer (PCa). PSMA is abundantly expressed on the surface of prostate cancer cells and within the neovasculature of other solid tumors, with limited expression in most normal tissues, establishing the basis for selective targeting of PCa lesions with PSMA-targeted agents. Among the rapidly increasing number of high-affinity PSMA ligands, ranging from intact antibodies to low-molecular-weight compounds, urea-based inhibitors have been most extensively leveraged, with expanding clinical use [1] .
Recently, a successful theranostic concept has been realized by the development of [ 68 Ga/ 177 Lu]PSMA-I&T [2] . Compared to first DOTA-conjugated EuK(=Glu-urea-Lys)-based inhibitors [3] , the DOTAGA-conjugate PSMA-I&T has been optimized with respect to PSMA affinity and in vivo stability [2, 4] [5, 6] . The success and ease of implementation of this theranostic approach, relies, among other factors, on the ability of DOTAGA to form stable complexes with a broad variety of radiometals [7] and on the negligible influence of radiometal exchange on the PSMA affinity of [*M 3+ ]PSMA-I&T (Table 1 ) [2] . In the present investigation, these characteristics were exploited to meet the clinical need for a corresponding gamma-emitting probe, which on the one hand allows for the intraoperative detection and identification of PSMA-positive tissues during surgery in patients with early recurrent or primary advanced PCa and on the other hand may additionally be employed for (preoperative) SPECT imaging (Fig. 1) . Given the suitable radionuclide characteristics of 111 In (t ½ = 2.8 d, E(γ) = 173, 245 keV) for the intended applications, PSMA-I&T was labeled with 111 In using a standard protocol and was evaluated preclinically and in a first patient.
As anticipated, [ In-PSMA-I&T 7.5 ± 1.5 104 ± 7 −4.5
Ga-PSMA-I&T 9.4 ± 2.9 59 ± 2 −4.3
Lu-PSMA-I&T 7.9 ± 2.4 76 ± 2 −4.1 PSMA affinities were determined in a competitive binding assay using LNCaP prostate cancer cells and ( 125 I-BA)KuE as radioligand [2] . Data represent means ± SD of n ≥ 3 separate determinations PSMA-specific ligand internalization was determined by incubation of LNCaP cells (37°C, 60 min) with the respective radioligands (0.2 nM) in the absence (total internalization) and presence (non-specific internalization) of 10 μM PMPA. Data were corrected for non-specific internalization and normalized to the specific internalization observed for the reference compound ( 125 I-BA)KuE in a parallel experiment [2] . Data are means ± SD (n = 3) Lipophilicities (from n-octanol/PBS partition coefficients P OW ) were determined using a shake-flask method; values are means from n = 6 determinations (Fig. 2) , in accordance with the identical PSMA affinity of both compounds.
Besides high tumor uptake, [ 111 In]PSMA-I&T also shows significant accumulation in tissues with endogenous PSMA expression, i.e., lung and in particular kidney and spleen (Fig. 1) 68 Ga]HBED-CC PSMA PET/CT for pre-therapeutic staging as previously described [8, 9] . Maximum intensity projection (MIP) showed intense tracer uptake in the primary tumor (Fig. 3a, solid arrow) as well as in multiple pelvic and retroperitoneal lymph node metastases (Fig. 3a, dotted arrows) . The patient was scheduled for radical prostatectomy facilitated by radioguided surgery to potentially enhance complete resection of lymph node metastases.
One day prior to surgery, the patient was injected with 155 MBq [
111 In]PSMA-I&T, and preoperative planar scintigraphy as well as SPECT/CT were performed at 4 h p.i. (Fig. 3b, e, h ). Radical prostatectomy as well as radioguided lymphadenectomy using a hand-held gamma probe with visual and acoustic feedback (Crystal Probe CXS-SG603; Crystal Photonics, Berlin, Germany) were performed 24 h after injection of [ (Fig. 3i, j) . Ventral and dorsal views of whole body planar scintigraphy (Fig. 3b) show intense [
111 In]PSMA-I&T uptake in the primary tumor (solid arrows) as well as in pelvic and retroperitoneal lymph node metastases (dotted arrows).
Axial [
111 In]PSMA-I&T SPECT/CT images confirm the intense tracer accumulation, both in the primary tumor ( Fig. 3e) and in a representative morphologically not enlarged lymph node (Fig. 3h ) and are consistent with [ 68 Ga]HBED-CC PSMA PET/CT findings (Fig. 3d, g ). In-autoradiography of cryosections from resected prostate tissue targeted intraoperative probe has recently been further pursued [10, 11] . In a small cohort of patients, [ 
